INBX data: INBRX-106 plus pembrolizumab shows efficacy in HNSCC
INBRX-106 plus pembrolizumab reported significant improvements in first-line HNSCC response rates, depth, and durability, especially in HPV-positive patients, with manageable safety. The study is planned to expand.